Edwards Lifesciences

US agency CMS has published a final national reimbursement guideline for TAVR that also provides reimbursement for asymptomatic aortic stenosis, thereby strengthening the TAVR market. Stifel views the decision as positive for Edwards Lifesciences and expects it to support the long-term revenue growth forecast of over 10%. The guideline retains case volume requirements and the role of the heart team including cardiac surgeons, but allows asynchronous chart review and requires only a single TAVR operator in the room, which increases procedural efficiency. CMS also announced a national review of reimbursement for TAVR in aortic regurgitation, expected to conclude on June 8, 2027. » Mere på de.investing.com

Aristotle Capital's Value Equity Fund highlighted Edwards Lifesciences for its leadership in transcatheter aortic valve replacement (TAVR) and structural heart therapies, citing the procedure's role in expanding patient eligibility and market adoption. The fund referenced Edwards' market position and recent stock range, with shares around $90.78 and a market cap near $51.8 billion. The mention came in the fund's Q2 2026 letter, which contrasted its own underperformance versus AI-driven index gains while still listing Edwards among notable holdings. 68 hedge funds held Edwards at the end of Q1 2026, up from 64 the prior quarter. » Mere på finance.yahoo.com

Shares of Edwards Lifesciences rose to a 52-week high of 92.94 USD and are currently trading just below that level; year-to-date the stock is up about 20.09%. The company trades at a P/E ratio of 50.01 and is considered overvalued by InvestingPro. At the New York Valves 2026 conference Edwards presented data from the PROGRESS study on TAVR, and the U.S. government proposed a National Coverage Decision memorandum for TAVR, which analysts view positively. Leerink reiterated "Market Perform" with a price target of 87 USD, TD Cowen raised its target to 104 USD; Theodora Mistras was also appointed as the new chief financial officer. » Mere på de.investing.com

Edwards Lifesciences shares rose to a 52-week high of $87.89 and are currently trading at $87.91. In Q1 2026 the company reported revenue of $1.65bn (+12.7% currency‑adjusted) and earnings per share of $0.78, both above expectations. Analysts revised their views: several firms raised price targets and ratings, while InvestingPro rates the stock as overvalued and several earnings forecasts were revised down. Theodora Mistras was also appointed as the new chief financial officer effective late May. » Mere på de.investing.com

Edwards Lifesciences has appointed Doretta Mistras as corporate vice president and CFO; she will assume the role at the end of May and succeeds Scott Ullem, who had already announced his departure and will remain as a strategic adviser during the transition. Mistras joins from Viatris, where she had served since March 2024 as CFO of the global finance organization and previously held leadership roles in healthcare investment banking at Citigroup and Goldman Sachs. The company has a market capitalization of $48 billion, revenue growth of 14% and a gross profit margin of nearly 78%; the stock is trading near its 52-week high. Analysts have recently cut their earnings forecasts (13 analysts), giving the CFO change added significance. » Mere på de.investing.com